Logotype for Praxis Precision Medicines Inc

Praxis Precision Medicines (PRAX) Investor Day 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Praxis Precision Medicines Inc

Investor Day 2026 summary

13 Nov, 2026

Strategy and commercial ambition

  • 2035 vision spans two platforms and four franchises; peak-sales guidance plus pipeline exceeds $20B: ulixacaltamide $10B, relutrigine $5B, vormatrigine $4B and elsunersen $1B.

  • Analyst consensus sales reach $13.5B in 2035 assuming approvals, with estimates adjusted for asset-specific probabilities of success.

  • Target to become a fully integrated CNS company within less than two years; launch infrastructure and full teams are being built ahead of approval for a broader portfolio, supported by patient services, data systems and AI-enabled automation.

  • Cerebrum combines neuronal physiology, computational design, pharmacology and genetics; Solidus aims to make RNA-based precision medicine discovery and development more repeatable. Strategy emphasizes mechanism-led development and disciplined, data-driven capital allocation.

Ulixacaltamide and essential tremor

  • Essential3 met primary and secondary endpoints; Day 56 mADL11 change was -4.3 vs. -1.7 with placebo (p<0.0001), and randomized-withdrawal response maintenance was 55% vs. 33% (p=0.037). FDA-requested sensitivity analyses remained significant.

  • Improvement was observed by Day 14; 19% improved by at least 12 TETRAS-ADL points at Day 56. Long-term data showed benefit through Week 95; an open-label snapshot of 68 patients showed mean improvement of 3 points at Week 12 and 6 at Week 95.

  • U.S. ET prevalence is estimated at 9M, rising to 11M by 2040; ~2M currently seek treatment. Planning price corridor is $50K–$100K WAC annually; illustrative math gives $1B sales at 1% penetration of 2M patients and $50K net price, not guidance.

  • Launch plan includes a ~300-person field team targeting ~19,000 HCPs, DTC education, titration support, and coordinated hub, digital-pharmacy and specialty-pharmacy services; team hiring is on track for completion before year-end.

  • PDUFA date is Jan. 29, 2027; FDA discussions include titration options. Planning accounts for possible DEA scheduling, including a 90-day process, delayed payer P&T activity and six-month prescriptions.

Relutrigine and epilepsy

  • PDUFA date for SCN2A/SCN8A DEE is Dec. 27, 2026. EMBOLD stopped early for efficacy, with a 53% placebo-adjusted motor-seizure reduction (p<0.0002) and 66% more motor seizure-free days than placebo (p=0.034).

  • Open-label extension seizure reduction reached ~86% at 18 months; 98% of eligible patients continued into the extension. Seizure-free days averaged 17.3 per 28 days vs. 10 on placebo.

  • Profile includes once-daily dosing, no titration or tapering, oral or feeding-tube liquid delivery, and ketogenic-diet compatibility; no drug-related SAEs or dose reductions in controlled experience. Clinicians and caregivers reported improvements including alertness, with 78% reporting improvement.

  • EMERALD broad-DEE topline was expected in Q4 2026; participants had a median 58 motor seizures per 28 days and used a median of 3 background ASMs. Broad DEE spans 50+ etiologies and is estimated at >300,000 people.

  • High-touch launch model includes caregiver engagement, centers of excellence, a specialty pharmacy, care coordinators and in-home education. SCN2A/SCN8A prevalence is at least 10,000; annual planning price is $400K–$600K WAC, with illustrative $1B sales at 2,500 patients and $5B combined at 12,500 patients.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Praxis Precision Medicines